FDA hands down a partial hold for PhI/II trial of Blueprint’s CDK2 inhibitor

On Friday, the Massachusetts-based biotech said the FDA informed Blueprint two days ago that it is placing a partial hold on a Phase I/II study, also known as the VELA trial, looking at BLU-222 in advanced solid tumors. The partial hold was due to adverse effects being observed in a “limited number” of patients, Blueprint said.